Tmigd3Tg(H2-K-CALR*)del52Shmd
Transgenic Allele Detail
|
Symbol: |
Tmigd3Tg(H2-K-CALR*)del52Shmd |
Name: |
transmembrane and immunoglobulin domain containing 3; transgene insertion del52, Kazuya Shimoda |
MGI ID: |
MGI:5909983 |
Synonyms: |
CALRdel52, Tg(H2-K-CALR*)del52Shmd |
Gene: |
Tmigd3 Location: Chr3:105778219-105831358 bp, + strand Genetic Position: Chr3, Syntenic
|
Alliance: |
Tmigd3Tg(H2-K-CALR*)del52Shmd page
|
|
|
Transgene Type: |
|
Transgenic (Dominant negative, Inserted expressed sequence) |
Mutation: |
|
Insertion
|
|
|
Tmigd3Tg(H2-K-CALR*)del52Shmd expresses
1 gene
Transgene expresses:
Organism |
Expressed Gene |
Homolog in Mouse |
Note |
human |
CALR (811) |
|
type 1 mutation (del52) with 52 bp deletion found in essential thrombocythemia (ET) patients |
|
|
|
Mutation details: The transgene is constructed with a mouse promoter and a mutated human cDNA, using the pSP65-H2K-i-LTR vector. The human cDNA is for the type 1 mutation (del52) that has a 52 bp deletion in exon 9, commonly found in essential thrombocythemia (ET) patients. Two copies of the transgene were found to have inserted head-to-head into intron 5 of the host gene. RT-PCR experiments confirmed expression from the transgene.
(J:241724)
|
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
Carrying any Tmigd3 Mutation: |
6 strains or lines available
|
|
Original: |
J:241724 Shide K, et al., Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia. 2017 May;31(5):1136-1144 |
All: |
2 reference(s) |
|